PALO ALTO, Calif., March 27, 2014 /PRNewswire/ -- Nora Therapeutics, a biotechnology company focused on developing therapeutics to address unmet needs in reproductive medicine, today announced that Dennis M. Fenton, Ph.D. has been elected to the company's board of directors. Dr. Fenton is a recognized pioneer in the biopharmaceutical industry, and retired from Amgen in 2008 as its Executive Vice President of Operations. During his 25-year tenure at Amgen, he had executive leadership roles in operations, manufacturing, engineering, process development, and sales and marketing.
"We are very pleased to welcome Dennis to Nora's board of directors," said Donald Hayden, Chairman of Nora's board of directors. "Having served on several boards of biopharmaceutical companies during their formative periods, Dr. Fenton has insights, expertise, and experience that will be invaluable to Nora as we advance our lead compound, NT100, toward the marketplace," added Jeffrey K. Tong, Ph.D., President and CEO of Nora Therapeutics.
Dr. Fenton serves on the board of directors of Hospira, Kythera Biopharmaceuticals, Dendreon, and XenoPort. He is a member of the scientific advisory board of PBS Biotech, and also serves on the board of trustees of the Keck Graduate Institute and of Rutgers University. Dr. Fenton received a B.S. in biology from Manhattan College and received his Ph.D. in microbiology from Rutgers University.
About Nora Therapeutics, Inc.
Nora Therapeutics is a privately-held biotechnology company focused on developing therapeutics to address IVF failure and recurrent pregnancy loss, two reproductive conditions with significant unmet need. Nora's lead compound, NT100, is a novel biologic agent similar to a naturally occurring protein in the female reproductive tract and may better enable embryo implantation and pregnancy maintenance by optimizing maternal-fetal immune tolerance. For more information, please visit www.noratherapeutics.com.
SOURCE Nora Therapeutics